[Rescue treatments for multiple sclerosis].
Weinshenker
Brian G
BG
Department of Neurology, Mayo Clinic College of Medicine, 200, First Street, SW, Rochester, MN 55905, USA.
D000074323:Alemtuzumab; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000627:therapeutic use; D018450:Disease Progression; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000008:administration & dosage; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008942:Mitoxantrone / Q000627:therapeutic use; D009103:Multiple Sclerosis / Q000628:therapy*; D000069442:Natalizumab; D010951:Plasma Exchange
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm; D000970:Antineoplastic Agents; D016756:Immunoglobulins, Intravenous; D007166:Immunosuppressive Agents; D000069442:Natalizumab; D000074323:Alemtuzumab; D003520:Cyclophosphamide; D008942:Mitoxantrone